
|Articles|December 17, 2008
Novel conjunctivitis drug recommended by FDA
Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.
Advertisement
Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.
Besifloxacin, a broad-spectrum fluoroquinolone anti-microbial agent, works by inhibiting inflammation in THP-1 monocytes.
The FDA recommendation is a step towards final approval; if approved, Bausch & Lomb aims to bring besifloxacin to the market next year.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Port Delivery System Therapies in Retinal Vascular Diseases
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5






















